Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Oncology
GSK and Ideaya seal synthetic lethality pact
by Lisa M. Jarvis
June 20, 2020
| A version of this story appeared in
Volume 98, Issue 24
GlaxoSmithKline will pay Ideaya Bioscience $100 million to gain access to three cancer drug–discovery programs. The deal, which includes an equity stake in the biotech worth $20 million, centers on finding drugs that exploit the concept of synthetic lethality, wherein a cancer cell can survive without one gene but dies if a second gene is crippled. GSK is buying into three synthetic lethality targets—MAT2A, Pol Theta, and Werner Helicase—for which Ideaya says it has solved crystal structures and made preclinical progress.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X